
NAME: David R. Spigel, MD

INSTITUTION: Sarah Cannon Research Institute/Texas Oncology

OPEN SEAT: Society Board of Directors Designated Community Oncologist

A. EDUCATION, POSTDOCTORAL TRAINING, LICENSURE & CERTIFICATION

Education:

2001		Harvard School of Public Health, Summer Program in Clinical Effectiveness, Boston, MA
1996	M.D.	University of Tennessee College of Medicine, Memphis, TN
1992	B.A.	Tulane University (History), New Orleans, LA

Postdoctoral Training:

2000-2003		Fellow, Hematology and Oncology, The Dana-Farber Cancer Institute, Boston, MA
2000		Chief Resident, Internal Medicine, Indiana University Medical Center, Indianapolis, IN
1999		Resident, Internal Medicine, Indiana University Medical Center, Indianapolis, IN
1996-1997		Intern, Internal Medicine, Indiana University Medical Center, Indianapolis, IN

Licensure and Certification:

2004, 2014		Diplomat, American Board of Internal Medicine - Oncology
2002		Tennessee License
2001		Diplomat, American Board of Internal Medicine

B. APPOINTMENTS

Clinical Appointments

2021-		Co-Director Hematology/Oncology Graduate Medical Education, Centennial Medical Center, Nashville, TN
2016-		Chief Scientific Officer, Sarah Cannon Research Institute. Nashville, TN
2012-		Director, Late Phase Research, Tennessee Oncology, PLLC, Nashville, TN
2006-2020		Director, Lung Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN
2006-present		Partner, Tennessee Oncology, PLLC, Nashville, TN
2003-2006		Associate Director of Clinical Research, Sarah Cannon Research Institute, Nashville, TN
2003-2006		Associate, Tennessee Oncology, PLLC, Nashville, TN

Academic Appointments:

2000-2003		Clinical Fellow in Medicine, Harvard Medical School, Boston, MA
-----------	--	---

Hospital Appointments:

2003-present		Centennial Medical Center, Nashville, TN
2000-2003		Dana-Farber Cancer Institute, Boston, MA

2000-2003	Brigham and Woman's Hospital, Boston, MA
2000-2003	Massachusetts General Hospital, Boston, MA
1996-2000	Wishard Memorial Hospital, Indianapolis, IN
1996-2000	Indiana University Hospital, Indianapolis, IN
1996-2000	Methodist Hospital, Indianapolis, IN
1996-2000	Roudebush Veteran's Affair Medical Center, Indianapolis, IN

C. PROFESSIONAL SOCIETIES, COMMITTEE ASSIGNMENTS, EDITORIAL BOARDS, AND TEACHING EXPERIENCE

Professional Societies:

American Association of Cancer Research
 American College of Physicians
 American Society of Clinical Oncology
 Association of Community Cancer Centers
 Cancer Genomics Consortium
 European Society of Medical Oncology

Committee Assignments:

American Association of Cancer Research

2017 Member, 2018 Annual Meeting Scientific Committee, Diversity Track
 2011 Member, Scientific Review Committee charged with selecting the recipient of the 2011 AACR Gertrude B. Elion Cancer Research Award

American Cancer Society Memorial Foundation Hope Lodge-Nashville, TN

2004-2006 Member, Advisory Board

American Society of Breast Disease

2008 Member, Symposium Poster Abstract Review Committee
 2006-2007 Member, Regional Symposia Planning Committee

American Society of Clinical Oncology

2021- Member, Therapy for Stage IV Non-Small-Cell Lung Cancer with/without Driver Alterations Sub-Committee
 2017-2018 Chair, 2018 Annual Meeting Education Committee
 2016-2019 Member, Clinical Practice Guideline Committee
 2014-2016 Member, Lung Cancer Education Committee
 2005- Member, Adjuvant Lung Cancer Guidelines Sub-Committee
 2007-2010 Member, Cancer Education Committee
 2008-2009 Track Leader, Cancer Clinical Trials Track, Cancer Education Committee

Association of Community Cancer Care Centers

2021-present Member, Board of Trustees
 2011 Member, Histology/Molecular Testing NSCLC Committee

Centennial Medical Center

2021-present Director, Oncology Graduate Medical Education

2017-2019	Chair, Board of Trustees
2015-2016	Member, Continuing Medical Education Committee
2014-2019	Member, Board of Trustees
2014-present	Member, Lung Cancer Working Group
2009-present	Director, Cancer Conferences
2009-present	Member, Oncology Leadership Team
2006-present	Member, Lung Cancer Multidisciplinary Team
2011-2013	Member, Medical Executive Committee
2011-2013	Chair, Department of Oncology
2009-2015	Chair, Cancer Committee
2007-2009	Member, Credentials Committee

Centers for Medicare and Medicaid Services

2007-2009	Member, Medicare Evidence Development Coverage Advisory Committee (MedCAC)
-----------	--

Clarian Healthcare

1999-2000	Member, Medical Education Committee
1999-2000	Member, Pharmacy and Therapeutics Committee

Free to Breathe (formerly The National Lung Cancer Partnership)

2011-2017	Member, Board of Directors
2011-2017	Member, Scientific Advisory Committee
2011-2017	Member, Grant Selection Committee

Indiana University Hospital

1999-2000	Member, Indiana University Hospital Planning Committee
1999-2000	Member, Indiana University School of Medicine Graduate Medical Education Committee
1999-2000	Member, Indiana University School of Medicine Residency Selection Committee

International Association for the Study of Lung Cancer

2021	Member, Phase II/III Clinical Trials Session Planning Committee, World Conference on Lung Cancer 2021
2013-2017	Chair, Publications Committee
2016-2017	Member, Immunology and Immunotherapy Scientific Planning Committee, 2017 IASLC 18 th World Conference on Lung Cancer, Yokohama, Japan
2015-2016	Member, Squamous Lung Cancer Committee
2015-2016	Member, Immunology and Immunotherapy Scientific Planning Committee, 2016 IASLC 17 th World Conference on Lung Cancer, Vienna Austria
2014-2015	Member, Ad Hoc Committee for Community Education Track, 2015 IASLC 16 th World Conference on Lung Cancer, Denver, CO
2014-2018	Member, Publications Committee

Lung Cancer Research Foundation

2018-	Member, Scientific Steering Committee
-------	---------------------------------------

Massachusetts Medical Society

2002-2003	Member, Committee on Geriatric Medicine
2001-2002	Member, Committee on Medical Practice

Pearl Point (formerly The Minnie Pearl Cancer Foundation)

2009-2011	Member, Physician Advisory Council
2004-2009	Member, Executive Committee
2004-2009	Member, Board of Directors
2008-2009	Member, Patient Services Committee
2007-2008	Member, Executive Director Search Committee

Tennessee Oncology, PLLC

2008-Present	Member, Board of Governors
2010-2014	Member, Tennessee Oncology Research Institute Board of Governors

University School of Nashville

2022-present	Member, Board of Trustees
--------------	---------------------------

Via Oncology

2015-present	Member, Lung Cancer Pathway Committee
2015-2018	Co-Chair, Lung Cancer Pathway Committee

Editorial Boards:

2009-2020	Editor, <i>Targeted Therapies</i>
2009-2020	Editor, <i>Oncology & Biotech News</i>
2009-2020	Editor, <i>Contemporary Oncology</i>
2010-2020	Editor, <i>World Journal of Clinical Oncology</i>
2006-2007	Author, "Biologic Therapies" Section - Journal Scan, <i>MedScape</i>
2003-2006	Contributing Editor, The Women's Oncology Review
2002-2006	Section Editor, "Outcomes in Research in Review" <i>Journal of Clinical Outcomes Management</i>

Ad Hoc Reviewer:

Breast Diseases: A Year Book Quarterly
Biomarker Insights
BMC Cancer
Cancer
Cancer Chemotherapy and Pharmacology
Clinical Advances in Hematology & Oncology
Clinical Breast Cancer
Clinical Lung Cancer
Community Oncology
Contemporary Oncology
Drugs
Future Oncology
Lung Cancer
Journal of Clinical Oncology
Oncology
Personalized Medicine
The Journal of Clinical Outcomes Management
The Lancet
The Medical Letter
Therapeutic Advances in Medical Oncology
World Journal of Surgical Oncology

Teaching Experience:

2004, 2005	Lecturer – Noon Conference, University of Tennessee College of Medicine, Internal Medicine Residency Program, Baptist Hospital, Nashville, TN
2002, 2003	Preceptor, Introduction to Clinical Medicine, Harvard University Medical School
2000	Preceptor, Introduction to Clinical Medicine, Indiana University Medical School

D. AWARDS AND HONORS

Awards and Honors:

- 2021 Discussant, *Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic: A Workshop on Lessons Learned*. National Academies of Sciences, Engineering, and Medicine, July 26-27, 2021
- 2020 Discussant (LBA5), Plenary Session 2020 ASCO Annual Meeting
- 2020 Fellow, American Society of Clinical Oncology
- 2018 Speaker, Session: ASCO/European Cancer Organization (ECCO) Joint Session: Access and Innovation With Multiplex Genomic Testing. 'Reimbursement and Payment of Multiplex Testing in the United States', 2018 ASCO Annual Meeting
- 2018 Chair, Session: ASCO Voices, 2018 ASCO Annual Meeting
- 2017 Chair, Session: Clinical Science Symposium 'Hitting the Target: Antibody-Drug Conjugates', 2018 ASCO Annual Meeting
- 2017 Speaker, Session: Is Tissue Still the Issue? Pathology Issues in Thoracic Oncology. 'Too Much Information: Separating the Wheat from the Chaff in Next Generation Sequencing reports and How to Use them in Clinical Practice', 2017 ASCO Annual Meeting
- 2017 Keynote speaker, Cancer Genomics Consortium 2017 Annual Meeting
- 2016 Speaker, Session: Challenges of Immunotherapeutics. 'Immunotherapeutics: Changes in the Landscape of Advanced Cancer Care', 2017 ASCO Palliative and Supportive Care in Oncology Symposium
- 2016 Discussant, Session: Developmental Therapeutics. 'Moving Forward with Checkpoints', 2016 ASCO Annual Meeting
- 2015-2020 Castle Connolly/Nashville Lifestyles 'Top Doctors'
- 2011, 2014 U.S. News and World Report 'Top Doctors in Tennessee'
- 2009-2016 Best Doctors in America, Best Doctors, Inc.
- 2011 Nashville Business Journal "Healthcare Hero" Award, Nashville, TN
- 2009 The International Association for the Study of Lung Cancer 13th World Conference on Lung Cancer Dr. Heine Hansen Lectureship in Small-Cell Lung Cancer, San Francisco, CA, 2009
- 2008 Nashville Business Journal "Healthcare Innovator" Award, Nashville, TN
- 2002 Partners in Excellence Award - Code-Team - Dana-Farber Cancer Institute, Boston, MA
- 2002 Cancer Education Consortium Clinical Pharmacology Workshop Award, Leesburg, VA
- 2000 Outstanding House Officer Award, Indiana University Medical Center
- 1992 Best Active Award, Zeta Beta Tau, Sigma Chapter, Tulane University
- 1992 Tulane Honor Society

1992	Montgomery History Prize, Tulane University
1992	Japan-Tulane Friendship Consulate Award, New Orleans, LA
1992	Phi Beta Kappa, Tulane University
1992	<i>Magna cum laude</i> , Tulane University
1992	President, Alpha Epsilon Delta Medical Chapter, Tulane University

E. BIBLIOGRAPHY

Original Articles

1. Cripe LD, Gelfanov VM, Smith EA, Spigel DR, et al. Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation. *Leukemia*. 2002;16(5):799-812.
2. Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. *JAMA*. 292(12):1480-9, 2004 Sep 22.
3. Spigel DR, Hainsworth JD, Burkett ER, et al, Single-Agent Gefitinib in Patients with Untreated Advanced Non-Small Cell Lung Cancer and Poor Performance Status: A Minnie Pearl Cancer Research Network Phase II Trial. *Clinical Lung Cancer*. 7(2):127-132, 2005.
4. Hainsworth JD, Spigel DR, Raefsky EL, et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site. *Cancer*. 2005 Aug 29;
5. Greco FA. Thompson DS. Morrissey LH. Erland JB. Burris HA 3rd. Spigel DR. et al. Hainsworth JD. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. *Oncologist*. 10(9):728-33, 2005 Oct.
6. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. *Journal of Clinical Oncology*. 23(31):7889-96, 2005 Nov 1.
7. Hainsworth JD, Meluch AA, Spigel DR, et al. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate-specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network. *Clinical Genitourinary Cancer*. 4(4):287-92, 2006 Mar.
8. Hainsworth JD, Spigel, DR, Litchy S, Greco FA. Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study. *J Clin Oncol* 2006 24: 3548-3554.
9. Hainsworth JD, Yardley DA, Spigel DR, et al. Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. *Cancer Investigation*. 24(5):469-73, 2006 Aug-Sep.
10. Spigel DR, Hainsworth JD, Simons L, et al. Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*. 2(9):854-61, 2007 Sep.
11. Hainsworth JD, Spigel DR, Farley C, et al. Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network. *J Clin Oncol* 2007 25: 1747-1752.
12. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. *Journal of Clinical Oncology*. 25(24):3644-8, 2007 Aug 20.

13. Hainsworth JD, Meluch AA, Spigel DR, et al. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. *Clinical Genitourinary Cancer*. 5(4):278-83, 2007 Mar.
14. Greco FA, Spigel DR, Kuzur ME, et al. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. *Clinical Lung Cancer*. 8(8):483-7, 2007 Sep.
15. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis PM, Gaspar LE, Pass HI, Spigel DR, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIa Resectable Non-Small-Cell Lung Cancer Guideline. *J Clin Oncol* 2007 0: JCO.2007.14.1226.
16. Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. *Cancer*. 2007 Nov 1;110(9):2027-34.
17. Hainsworth JD, Spigel DR, Sosman JA, et al. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. *Clin Genitourin Cancer*. 2007 Dec;5(7):427-32.
18. Hainsworth JD, Vazquez ER, Spigel DR, et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. *Cancer*. 2008 Mar 15;112(6):1288-95.
19. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.] *Journal of Clinical Oncology*. 26(15):2442-9, 2008 May 20.
20. Spigel DR, Lin M, O'Neill V, Hainsworth JD. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. *Cancer*. 112(12):2749-55, 2008 Jun 15.
21. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. *Journal of Clinical Oncology*. 26(27):4442-8, 2008 Sep 20.
22. Hainsworth JD, Spigel DR, Barton J, et al. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. *Cancer*. 113(4):765-71, 2008 Aug 15.
23. Yardley DA, Burris HA 3rd, Farley CP, Barton JH, Peacock NW, Spigel DR, Greco FA, Hainsworth JD. A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer. *Clinical Breast Cancer*. 8(3):242-8, 2008 Jun.
24. Jones S, Thompson D, Barton J, Patton J, Shipley D, Greco FA, Spigel D, Infante J, Burris HA 3rd. A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. *Clinical Lung Cancer*. 9(3):154-9, 2008 May.
25. Yardley DA, Burris III HA, Simons L, Spigel DR, et al. A Phase II Trial of Gemcitabine/Carboplatin with or Without Trastuzumab in the First-Line Treatment of Patients with Metastatic Breast Cancer. *Clinical Breast Cancer*. 8(5):425-31, 2008 Oct.
26. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. *Journal of Clinical Oncology*. 27(5):672-80, 2009 Feb 10
27. Infante JR, Yardley DA, Burris III HA, Greco FA, Farley CP, Webb C, Spigel DR, Hainsworth JD. Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer. *Clinical Breast Cancer*. 9(1):23-8, 2009 Feb.

28. Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Neoadjuvant chemotherapy/ gefitinib followed by concurrent chemotherapy/radiation therapy/ gefitinib for patients with locally advanced squamous carcinoma of the head and neck. *Cancer*. 115(10):2138-46, 2009 May 15.
29. Yardley DA, Burris III HA, Hanson S, Greco FA, Spigel DR, Barton J, Hainsworth JD. Weekly Gemcitabine and Trastuzumab in the Treatment of Patients with HER2-Overexpressing Metastatic Breast Cancer. *Clinical Breast Cancer*. 9(3):178-83, 2009 Aug.
30. Hainsworth JD, Spigel DR, Markus TM, et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. *Clinical Lymphoma & Myeloma*. 9(3):223-8, 2009 Jun.
31. Yardley DA, Burris HA 3rd, Spigel DR, et al. A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer. *Clinical Breast Cancer*. 9(4):247-52, 2009 Nov.
32. Yardley DA, Burris HA 3rd, Markus T, et al. Phase II trial of docetaxel plus imatinib mesylate in the treatment of patients with metastatic breast cancer. *Clinical Breast Cancer*. 9(4):237-42, 2009 Nov.
33. Cohen RB, Jones SF, Aggarwal C, von Mehren M, Cheng J, Spigel DR, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. *Clinical Cancer Research*. 15(21):6694-701, 2009 Nov 1.
34. Spigel DR, Greco FA, Zubkus JD, et al. Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*. 4(12):1555-60, 2009 Dec.
35. Hainsworth JD, Spigel DR, Thompson DS, et al. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. *Oncologist*. 14(12):1189-97, 2009 Dec.
36. Spigel, DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. *J Clin Oncol*. 2010 Jan 1;28(1):43-8.
37. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. *Cancer Journal*. 16(1):70-5, 2010 Jan-Feb.
38. Hainsworth JD, Flinn IW, Spigel DR, et al. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. *Clinical lymphoma, myeloma & leukemia*. 10(1):44-50, 2010 Feb.
39. Hainsworth JD, Meluch AA, Lane CM, Spigel DR, et al. Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium. *Cancer Investigation*. 28(3):275-9, 2010 Mar.
40. Spigel DR, Greco FA, Thompson DS, et al. Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer. *Clinical Lung Cancer*. 11(3):198-203, 2010 May.
41. Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. *Cancer*. 116(10):2448-54, 2010 May 15.
42. Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. *Journal of Clinical Oncology*. 28(13):2131-6, 2010 May.
43. Spigel DR, Greco FA, Meluch AA, et al. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. *Journal of Clinical Oncology*. 28(13):2213-9, 2010 May 1.

44. Spigel DR, Hainsworth JD, Lane CM, et al. Phase II trial of vinflunine in relapsed small cell lung cancer. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*. 5(6):874-8, 2010 Jun.
45. Spigel DR, Hainsworth JD, Gandhi JG, et al. A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*. 5(6):862-6, 2010 Jun.
46. Spigel DR, Hainsworth JD, Barton JH, et al. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*. 5(6):841-5, 2010 Jun.
47. Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ, Hainsworth JD. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. *Oncologist*. 15(5):500-6, 2010.
48. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. *Journal of Clinical Oncology*. 28(15):2598-603, 2010 May 20.
49. Spigel DR, Greco FA, Waterhouse D, et al. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer. *Clinical Advances in Hematology & Oncology*. 8(7):480-5, 498, 2010 Jul
50. Burris HA 3rd, Infante JR, Jewell RC, Spigel DR, Greco FA, Thompson DS, Jones SF. A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies. *Oncologist*. 15(9):954-60, 2010.
51. Hainsworth JD, Infante JR, Spigel DR, et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. *Cancer*. 116(17):4122-9, 2010 Sep 1.
52. Infante JR, Jones SF, Bendell JC, Spigel DR, et al. A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. *European Journal of Cancer*. 47(2):199-205, 2011 Jan.
53. Krug LM, Crawford J, Ettinger DS, Shapiro GI, Spigel D, Reiman T, Temel JS, Michelson GC, Young DY, Hoch U, Adelman DC. Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*. 6(2):384-6, 2011 Feb.
54. Jones SF, Bendell JC, Infante JR, Spigel DR, Thompson DS, Yardley DA, Greco FA, Murphy PB, Burris HA 3rd. A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors. *Clinical Advances in Hematology & Oncology*. 9(3):225-30, 2011 Mar.
55. Spigel DR, Hainsworth JD, Burris HA 3rd, Molthrop DC, Peacock N, Kommor M, Vazquez ER, Greco FA, Yardley DA. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer. *Clinical Advances in Hematology & Oncology*. 9(4):280-6, 2011 Apr.
56. Spigel DR, Greco FA, Burris HA 3rd, Shipley DL, Clark BL, Whorf RC, Arrowsmith ER, Hainsworth JD. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer. *Clinical Lung Cancer*. 12(3):187-91, 2011 May.
57. Spigel D, Jones S, Hainsworth J, Infante J, Greco FA, Thompson D, Doss H, Burris H. A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies. *Cancer Investigation*. 29(4):308-12, 2011 May.
58. Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. *Journal of Clinical Oncology*. 29(16):2215-22, 2011 Jun 1.

59. Spigel DR, Burris HA 3rd, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. *Journal of Clinical Oncology*. 29(18):2582-9, 2011 Jun 20.
60. Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. *Cancer Investigation*. 29(7):451-5, 2011 Aug.
61. Hainsworth JD, Spigel DR, Greco FA, Shipley DL, Peyton J, Rubin M, Stipanov M, Meluch A. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium. *Cancer Journal*. 17(5):267-72, 2011 Sep.
62. Ramalingam SS, Spigel DR, Chen D, Steins MB, Engelman JA, Schneider CP, Novello S, Eberhardt WE, Crino L, Habben K, Liu L, Janne PA, Brownstein CM, Reck M. Randomized Phase II Study of Erlotinib in Combination with Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*. 29(34):4574-80, 2011 Dec 1.
63. Spigel DR, Hainsworth JD, Shipley DL, Ervin TJ, Kohler PC, Lubiner ET, Peyton JD, Waterhouse DM, Burris HA 3rd, Greco FA. A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*. 7(1):196-202, 2012 Jan
64. Infante JR, Jones SF, Bendell JC, Greco FA, Yardley DA, Lane CM, Spigel DR, Hainsworth JD, Burris HA 3rd. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. *Cancer Chemother Pharmacol*. 2012 Jan;69(1):137-44. doi: 10.1007/s00280-011-1674-0. Epub 2011 May 28. PubMed PMID: 21626051.
65. Spigel DR, Bendell JC, McCleod M, Shipley DL, Arrowsmith E, Barnes EK, Infante JR, Burris HA 3rd, Greco FA, Hainsworth JD. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. *Clin Colorectal Cancer*. 2012 Mar;11(1):45-52. doi: 10.1016/j.clcc.2011.04.002. Epub 2011 Aug 15. PubMed PMID: 21840771.
66. Jones SF, Spigel DR, Yardley DA, Thomson DF, Burris, HA. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies *Clin Adv Hematol Oncol*. 2011 Nov;9(11):845-52.
67. Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT, Spigel DR. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. *Clin Adv Hematol Oncol*. 2012 Apr;10(4):240-6. PubMed PMID: 22706484.
68. Reck M, Barlesi F, Crinò L, Henschke CI, Isla D, Stiebeler S, Spigel DR. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. *Ann Oncol*. 2012 May;23(5):1111-20. doi: 10.1093/annonc/mdr463. Epub 2011 Nov 4. Review. PubMed PMID: 22056855; PubMed Central PMCID: PMC3335247.
69. Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. *Invest New Drugs*. 2012 Jun;30(3):1216-23. doi: 10.1007/s10637-011-9687-4. Epub 2011 May 19. Erratum in: *Invest New Drugs*. 2012 Jun;30(3):1272-3. PubMed PMID: 21594619.
70. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2. PubMed PMID: 22658127; PubMed Central PMCID: PMC3544539.

71. Jones SF, Infante JR, Spigel DR, Peacock NW, Thompson DS, Greco FA, McCulloch W, Burris HA 3rd. Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors. *Cancer Invest.* 2012 Jul;30(6):481-6. doi: 10.3109/07357907.2012.675382. Epub 2012 Apr 26. PubMed PMID: 22536933.
72. Burris HA 3rd, Dowlati A, Moss RA, Infante JR, Jones SF, Spigel DR, Levinson KT, Lindquist D, Gainer SD, Dar MM, Suttle AB, Ball HA, Tan AR. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. *Mol Cancer Ther.* 2012 Aug;11(8):1820-8. doi: 10.1158/1535-7163.MCT-11-0997. Epub 2012 Jun 7. PubMed PMID: 22679111.
73. Spigel DR, Greco FA, Rubin MS, Shipley D, Thompson DS, Lubiner ET, Eakle JF, Quinn R, Burris HA, Hainsworth JD. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. *Lung Cancer.* 2012 Aug;77(2):359-64. doi: 10.1016/j.lungcan.2012.03.009. Epub 2012 May 3. PubMed PMID: 22560921.
74. Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. *J Clin Oncol.* 2012 Aug 10;30(23):2829-36. doi: 10.1200/JCO.2011.41.4987. Epub 2012 Jul 2. PubMed PMID: 22753922.
75. Spigel DR, Anthony Greco F, Waterhouse DM, Shipley DL, Zubkus JD, Bury MJ, Webb CD, Hart LL, Gian VG, Infante JR, Burris HA 3rd, Hainsworth JD. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer. *Lung Cancer.* 2012 Oct;78(1):70-5. doi: 10.1016/j.lungcan.2012.06.008. Epub 2012 Sep 1. PubMed PMID: 22947511.
76. Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. *J Clin Oncol.* 2013 Jan 10;31(2):217-23. doi: 10.1200/JCO.2012.43.3755. Epub 2012 Oct 1. PubMed PMID: 23032625.
77. Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H; MetLung Phase III Study Group. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMab) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. *Clin Lung Cancer.* 2012 Nov;13(6):500-4. doi: 10.1016/j.clc.2012.05.009. PubMed PMID: 23063071.
78. Infante JR, Arkenau HT, Bendell JC, Rubin MS, Waterhouse D, Jones GT, Spigel DR, Lane CM, Hainsworth JD, Burris HA 3rd. Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial. *Cancer Biol Ther.* 2013 Apr;14(4):340-6. doi: 10.4161/cbt.23625. Epub 2013 Jan 28. PubMed PMID: 23358470; PubMed Central PMCID: PMC3667874.
79. Greco FA, Lenington WJ, Spigel DR, Hainsworth JD. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. *J Natl Cancer Inst.* 2013 Jun 5;105(11):782-90. doi: 10.1093/jnci/djt099. Epub 2013 May 2. PubMed PMID: 23641043.
80. Hainsworth JD, Spigel DR, Rubin MS, Boccia RV, Greco FA. Reply to M.-E. Percival et al and L.B. Saltz. *J Clin Oncol.* 2013 Jul 1;31(19):2514-5. PubMed PMID: 23967489.
81. Spigel DR, Waterhouse DM, Lane S, Legenne P, Bhatt K. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. *Clin Lung Cancer.* 2013 Jul;14(4):356-63. doi: 10.1016/j.clc.2012.12.003. Epub 2013 Feb 4. PubMed PMID: 23391616.
82. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, Blumenschein GR Jr, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. *J Clin Oncol.* 2013 Nov 10;31(32):4105-14. doi: 10.1200/JCO.2012.47.4189. Epub 2013 Oct 7. PubMed PMID: 24101053.

83. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Fridmott-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. *J Clin Oncol*. 2013 Dec 1;31(34):4349-57. doi: 10.1200/JCO.2012.47.9626. Epub 2013 Oct 21. PubMed PMID: 24145346.
84. Kubota K, Ichinose Y, Scagliotti G, Spigel D, Kim JH, Shinkai T, Takeda K, Kim SW, Hsia TC, Li RK, Tiangco BJ, Yau S, Lim WT, Yao B, Hei YJ, Park K. Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. *Ann Oncol*. 2014 Feb;25(2):529-36. doi: 10.1093/annonc/mdt552. Epub 2014 Jan 13. PubMed PMID: 24419239.
85. von Pawel J, Harvey JH, Spigel DR, Dediu M, Reck M, Cebotaru CL, Humphreys RC, Gribbin MJ, Fox NL, Camidge DR. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. *Clin Lung Cancer*. 2014 May;15(3):188-196.e2. doi: 10.1016/j.clcc.2013.12.005. Epub 2013 Dec 27. PubMed PMID: 24560012.
86. Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. *Clin Lung Cancer*. 2014 May;15(3):173-81. doi: 10.1016/j.clcc.2013.12.002. Epub 2013 Dec 27. Review. PubMed PMID: 24486058.
87. Novello S, Scagliotti GV, Sydorenko O, Vynnychenko I, Volovat C, Schneider CP, Blackhall F, McCoy S, Hei YJ, Spigel DR. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study. *J Thorac Oncol*. 2014 Aug;9(8):1154-61. doi: 10.1097/JTO.0000000000000227. PubMed PMID: 25157768.
88. Lynch TJ Jr, Spigel DR, Brahmer J, Fischbach N, Garst J, Jahanzeb M, Kumar P, Vidaver RM, Wozniak AJ, Fish S, Flick ED, Leon L, Hazard SJ, Kosty MP; ARIES Study Investigators. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. *J Thorac Oncol*. 2014 Sep;9(9):1332-9. doi: 10.1097/JTO.0000000000000257. PubMed PMID: 25122429.
89. Spigel DR, Peterson AC. Reply to A. Soultati et Al. *J Clin Oncol*. 2014 Nov 20;32(33):3781-2. doi: 10.1200/JCO.2013.54.9683. Epub 2014 Oct 20. PubMed PMID: 25332251.
90. von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schütte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. *J Clin Oncol*. 2014 Dec 10;32(35):4012-9. doi: 10.1200/JCO.2013.54.5392. Epub 2014 Nov 10. PubMed PMID: 25385727.
91. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. *J Thorac Oncol*. 2015 Jan;10(1 Suppl 1):S1-63. doi: 10.1097/JTO.0000000000000405. PubMed PMID: 25535693; PubMed Central PMCID: PMC4346098.
92. Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinchenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desai D, Treat JA, Govindan R, Ross HJ. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer. *J Thorac Oncol*. 2015 Jan;10(1):134-42. doi: 10.1097/JTO.0000000000000366. PubMed PMID: 25371077; PubMed Central PMCID: PMC4276572.
93. Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, Olsen MR, Winfree KB, Chen J, Liu J, Guba SC, Socinski MA, Bonomi P. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV

nonsquamous non-small-cell lung cancer. *J Thorac Oncol*. 2015 Feb;10(2):353-9. doi: 10.1097/JTO.0000000000000277. PubMed PMID: 25611228.

94. Chiappori AA, Kolevska T, Spigel DR, Hager S, Rarick M, Gadgeel S, Blais N, Von Pawel J, Hart L, Reck M, Bassett E, Burington B, Schiller JH. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. *Ann Oncol*. 2015 Feb;26(2):354-62. doi: 10.1093/annonc/mdu550. Epub 2014 Dec 2. PubMed PMID: 25467017; PubMed Central PMCID: PMC4304381.

95. Bendell JC, Jones SF, Hart L, Spigel DR, Lane CM, Earwood C, Infante JR, Barton J, Burris HA. A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. *Invest New Drugs*. 2015 Feb;33(1):187-93. doi: 10.1007/s10637-014-0177-3. Epub 2014 Oct 22. PubMed PMID: 25335932.

96. Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J Jr, Cao D, Alexandris E, Yurasov S, Camidge DR, Bonomi P. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. *Cancer*. 2015 Mar 15;121(6):883-92. doi: 10.1002/cncr.29132. Epub 2014 Nov 6. PubMed PMID: 25377507.

97. Greco FA, Lenington WJ, Spigel DR, Hainsworth JD. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay. *Mol Diagn Ther*. 2015 Apr;19(2):91-7. doi: 10.1007/s40291-015-0133-8. PubMed PMID: 25758902.

98. Wozniak AJ, Kosty MP, Jahanzeb M, Brahmer JR, Spigel DR, Leon L, Fish S, Flick ED, Hazard SJ, Lynch TJ Jr. Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study. *Clin Oncol (R Coll Radiol)*. 2015 Apr;27(4):187-96. doi: 10.1016/j.clon.2014.12.002. Epub 2015 Jan 7. PubMed PMID: 25576353.

99. Reynolds CH, Patel JD, Garon EB, Olsen MR, Bonomi P, Govindan R, Pennella EJ, Liu J, Guba SC, Li S, Spigel DR, Hermann RC, Socinski MA, Obasaju CK. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2015 May;16(3):200-8. doi: 10.1016/j.clcc.2014.11.004. Epub 2014 Nov 18. PubMed PMID: 25516338.

100. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2015 Jun 20;33(18):2004-12. doi: 10.1200/JCO.2014.58.3708. Epub 2015 Apr 20. PubMed PMID: 25897158.

101. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudalet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med*. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31. PubMed PMID: 26028407.

102. Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB. A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma. *Pigment Cell Melanoma Res*. 2015 Jul 14. doi: 10.1111/pcmr.12394. [Epub ahead of print] PubMed PMID: 26176864.

103. Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2015 Aug 20;33(24):2667-74. doi: 10.1200/JCO.2014.60.7317. Epub 2015 Jul 13. PubMed PMID: 26169611.

104. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufel M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med*. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27. PubMed PMID: 26412456.
105. Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIa Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. *J Clin Oncol*. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31. PubMed PMID: 26324372.
106. Rischin D, Spigel DR, Adkins D, Wein R, Arnold S, Singhal N, Lee O, Murugappan S. PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. *Head Neck*. 2016 Apr;38 Suppl 1:E1756-61. doi: 10.1002/hed.24311. Epub 2015 Dec 17.
107. Karlovich C, Goldman JW, Sun JM, Mann E, Sequist LV, Konopa K, Wen W, Angenendt P, Horn L, Spigel D, Soria JC, Solomon B, Camidge DR, Gadgeel S, Paweletz C, Wu L, Chien S, O'Donnell P, Matheny S, Despaigne D, Rolfe L, Raponi M, Allen AR, Park K, Wakelee H. Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). *Clin Cancer Res*. 2016 May 15;22(10):2386-95. doi: 10.1158/1078-0432.CCR-15-1260. Epub 2016 Jan 8.
108. Leon L, Kosty M, Jahanzeb M, Spigel D, Wozniak AJ, Brahmer J, Fish S, Flick ED, Hazard SJ, Lynch TJ. Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort study. *Pharmacoepidemiol Drug Saf*. 2016 May;25(5):569-77. doi: 10.1002/pds.3948. Epub 2016 Jan 8.
109. Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? *J Thorac Oncol*. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30.
110. Felip E, Crinò L, Kim DW, Spigel DR, Nishio M, Mok T, Scagliotti G, Cesic D, Sutradhar S, Shaw AT. 141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials. *J Thorac Oncol*. 2016 Apr;11(4 Suppl):S118-9. doi: 10.1016/S1556-0864(16)30251-9. Epub 2016 Apr 15.
111. Gerber DE, Spigel DR, Giorgadze D, Shtivelband M, Ponomarova OV, Shan JS, Menander KB, Belani CP. Docetaxel Combined with Baviximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2016 May;17(3):169-76.
112. Bendell JC, Bauer TM, Lamar R, Joseph M, Penley W, Thompson DS, Spigel DR, Owera R, Lane CM, Earwood C, Burris HA. A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors. *Cancer Invest*. 2016 Jul 2;34(6):265-70.
113. Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. *J Thorac Oncol*. 2016 Dec;11(12):2066-2081. doi: 10.1016/j.jtho.2016.08.138. Epub 2016 Aug 26.
114. Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCR16-001 investigators. Rovalpituzumab tesirine, a

DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. *Lancet Oncol.* 2017 Jan;18(1):42-51.

115. Socinski MA, Kaye FJ, Spigel DR, Kudrik FJ, Ponce S, Ellis PM, Majem M, Lorigan P, Gandhi L, Gutierrez ME, Nepert D, Corral J, Ares LP. Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. *Clin Lung Cancer.* 2017 Jan;18(1):68-76.e2.

116. Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Mocchi S, Phan S, Shames DS, Smith D, Yu W, Paton VE, Mok T. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. *J Clin Oncol.* 2017 Feb;35(4):412-420.

117. Burris HA, Bakewell S, Bendell JC, Infante J, Jones SF, Spigel DR, Weiss GJ, Ramanathan RK, Ogden A, Von Hoff D. Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort. 2017 Feb 23;1(6):e000154.

118. Salgia R, Stille JR, Weaver RW, McCleod M, Hamid O, Polzer J, Roberson S, Flynt A, Spigel DR. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. *Lung Cancer.* 2017 Mar;105:7-13.

119. Spigel DR, Luft A, Depenbrock H, Ramlau R, Khalil M, Kim JH, Mayo C, Chao GY, Obasaju C, Natale R. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer. *Clin Lung Cancer.* 2017 Mar 2. pii: S1525-7304(17)30045-1.

120. Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, Lin SH, Pass HI, Seth R, Shepherd FA, Spigel DR, Strawn JR, Ung YC, Weyant M. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. *J Clin Oncol.* 2017 Apr 24;JCO2017724401.

121. Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJL, Leach J, Edenfield WJ, Wang D, Grote HJ, Heydebreck AV, Chin K, Cuillerot JM, Kelly K. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. *Lancet Oncol.* 2017 May;18(5):599-610.

122. Salgia R, Weaver RW, McCleod M, Stille JR, Yan SB, Roberson S, Polzer J, Flynt A, Raddad E, Peek VL, Wijayawardana SR, Um SL, Gross S, Connelly MC, Morano C, Repollet M, Sanders R, Baeten K, D'Haese D, Spigel DR. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. *Invest New Drugs.* 2017 Jun;35(3):334-344.

123. Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol.* 2017 Jul;18(7):874-886.

124. Spigel DR, Mekhail TM, Waterhouse D, Hadley T, Webb C, Burris HA 3rd, Hainsworth JD, Greco FA. First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC). *Cancer Invest.* 2017 Aug 1:1-6.

125. Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufel M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). *J Clin Oncol.* 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12. PMID: 29023213; PMCID: PMC6075826.

126. Spigel DR, Rubin MS, Gian VG, Shipley DL, Burris HA 3rd, Kosloff RA, Shih KC, Quinn R, Greco FA, Hainsworth JD. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). *Lung Cancer*. 2017 Nov;113:79-84. doi: 10.1016/j.lungcan.2017.09.007. Epub 2017 Sep 18. PMID: 29110854.
127. Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C. nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. *Lung Cancer (Auckl)*. 2017 Oct 30;8:207-216. doi: 10.2147/LCTT.S138570. PMID: 29138610; PMCID: PMC5679693.
128. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. *J Clin Oncol*. 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10. Erratum in: *J Clin Oncol*. 2019 Feb 1;37(4):360. PMID: 29320312.
129. von Pawel J, Spigel DR, Ervin T, Losonczy G, Barlesi F, Juhász E, Anderson M, McCall B, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Reck M. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer. *Oncologist*. 2018 Jun;23(6):654-e58. doi: 10.1634/theoncologist.2017-0690. Epub 2018 Feb 7. PMID: 29438092; PMCID: PMC6067939.
130. Spigel DR, Hainsworth JD, Joseph MJ, Shipley DL, Hagan MK, Thompson DS, Burris HA 3rd, Greco FA. Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2. *Cancer*. 2018 May 1;124(9):1982-1991. doi: 10.1002/cncr.30986. Epub 2018 Feb 16. PMID: 29451696.
131. Spigel DR, Hainsworth JD, Shipley DL, Mekhail TM, Zubkus JD, Waterhouse DM, Daniel DB, Burris HA 3rd, Greco FA. Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium. *Lung Cancer*. 2018 Mar;117:38-43. doi: 10.1016/j.lungcan.2018.01.007. Epub 2018 Jan 12. PMID: 29496254.
132. Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G Jr. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). *J Thorac Oncol*. 2018 May;13(5):682-688. doi: 10.1016/j.jtho.2018.02.022. Epub 2018 Mar 6. PMID: 29518553.
133. Hainsworth JD, Waterhouse DM, Shih KC, Boccia RV, Priego VM, McCleod MJ, Kudrik FJ, Mitchell RB, Burris HA 3rd, Greco FA, Spigel DR. Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC). *Lung Cancer*. 2018 Apr;118:6-12. doi: 10.1016/j.lungcan.2018.01.009. Epub 2018 Jan 31. PMID: 29572004.
134. Spigel DR, Burris HA 3rd, Greco FA, Shih KC, Gian VG, Lipman AJ, Daniel DB, Waterhouse DM, Finney L, Heymach JV, Hainsworth JD. Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. *Cancer*. 2018 Jun 1;124(11):2355-2364. doi: 10.1002/cncr.31290. Epub 2018 Apr 12. PMID: 29645086.
135. Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. *Cancer Discov*. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17. PMID: 29773717; PMCID: PMC6030433.

136. Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ, Leon L, Fredrickson J, Kowanetz M, Sandler A, Funke R, Rizvi NA. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. *J Thorac Oncol*. 2018 Nov;13(11):1733-1742. doi: 10.1016/j.jtho.2018.05.004. PMID: 29775807; PMCID: PMC7455890.
137. Young K, Paz-Ares L, Thatcher N, Spigel DR, Shahidi J, Soldatenkova V, Grau G, Kurek R, Shepherd FA. Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis. *Thromb Res*. 2018 Jul;167:50-56. doi: 10.1016/j.thromres.2018.05.004. Epub 2018 May 7. PMID: 29787943.
138. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Reply to J.J. Tao et al. *J Clin Oncol*. 2018 Aug 10;36(23):2451. doi: 10.1200/JCO.2018.78.6392. Epub 2018 Jun 1. PMID: 29856693.
139. Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. *Eur J Cancer*. 2018 Sep;101:201-209. doi: 10.1016/j.ejca.2018.06.031. Epub 2018 Aug 1. PMID: 30077125.
140. Gajra A, Karim NA, Mulford DA, Villaruz LC, Matrana MR, Ali HY, Santos ES, Berry T, Ong TJ, Sanford A, Amiri K, Spigel DR. nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2. *Front Oncol*. 2018 Jul 24;8:253. doi: 10.3389/fonc.2018.00253. PMID: 30087850; PMCID: PMC6066533.
141. Reck M, Brahmer J, Bennett B, Taylor F, Penrod JR, DeRosa M, Dastani H, Spigel DR, Gralla RJ. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. *Eur J Cancer*. 2018 Oct;102:23-30. doi: 10.1016/j.ejca.2018.05.005. Epub 2018 Aug 10. PMID: 30103096.
142. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Huret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. *N Engl J Med*. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25. PMID: 30280658.
143. Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE 3rd, Wistuba I, Chaft J, Rizvi NA, Spigel DR, Spira A, Hirsch FR, Cohen V, Smith D, Boyd Z, Miley N, Flynn S, Leveque V, Shames DS, Ballinger M, Mocchi S, Shankar G, Funke R, Hampton G, Sandler A, Amler L, Mellman I, Chen DS, Hegde PS. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). *Proc Natl Acad Sci U S A*. 2018 Oct 23;115(43):E10119-E10126. doi: 10.1073/pnas.1802166115. Epub 2018 Oct 8. PMID: 30297397; PMCID: PMC6205493.
144. Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, Spigel DR, Moreno V, Chau I, Hann CL, Eder JP, Steele NL, Pieters A, Fairchild J, Antonia SJ. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. *J Thorac Oncol*. 2019 Feb;14(2):237-244. doi: 10.1016/j.jtho.2018.10.003. Epub 2018 Oct 10. PMID: 30316010; PMCID: PMC8050700.
145. Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. *J Clin Oncol*. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20. PMID: 30785829; PMCID: PMC6494267.
146. Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. *Lancet Oncol*. 2019 Apr;20(4):518-530. doi: 10.1016/S1470-2045(18)30904-5. Epub 2019 Mar 8. PMID: 30857956; PMCID: PMC6781620.

147. Spigel DR, McCleod M, Jotte RM, Einhorn L, Horn L, Waterhouse DM, Creelan B, Babu S, Leighl NB, Chandler JC, Couture F, Keogh G, Goss G, Daniel DB, Garon EB, Schwartzberg LS, Sen R, Korytowsky B, Li A, Aanur N, Hussein MA. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). *J Thorac Oncol*. 2019 Sep;14(9):1628-1639. doi: 10.1016/j.jtho.2019.05.010. Epub 2019 May 20. PMID: 31121324.
148. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, McHenry MB, Hoseney F, Harbison CT, Grosso JF, Sznol M. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. *JAMA Oncol*. 2019 Oct 1;5(10):1411-1420. doi: 10.1001/jamaoncol.2019.2187. PMID: 31343665; PMCID: PMC6659167.
149. Spigel DR, Shipley DL, Waterhouse DM, Jones SF, Ward PJ, Shih KC, Hemphill B, McCleod M, Whorf RC, Page RD, Stilwell J, Mekhail T, Jacobs C, Burris HA 3rd, Hainsworth JD. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial. *Oncologist*. 2019 Dec;24(12):e1409-e1416. doi: 10.1634/theoncologist.2018-0518. Epub 2019 Aug 16. PMID: 31420467; PMCID: PMC6975937.
150. Gerber DE, Infante JR, Gordon MS, Goldberg SB, Martín M, Felip E, Martinez Garcia M, Schiller JH, Spigel DR, Cordova J, Westcott V, Wang Y, Shames DS, Choi Y, Kahn R, Dere RC, Samineni D, Xu J, Lin K, Wood K, Royer-Joo S, Lemahieu V, Schuth E, Vaze A, Maslyar D, Humke EW, Burris HA 3rd. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. *Clin Cancer Res*. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965. Epub 2019 Sep 20. PMID: 31540980.
151. Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste JF, Spigel DR, Wadsworth C, Taboada M, Dennis PA, Özgüroğlu M, Antonia SJ. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. *J Thorac Oncol*. 2020 Feb;15(2):288-293. doi: 10.1016/j.jtho.2019.10.002. Epub 2019 Oct 14. PMID: 31622733; PMCID: PMC7244187.
152. Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, Antonia SJ, Ascierto PA, Moreno V, Atmaca A, Salvagni S, Taylor M, Amin A, Camidge DR, Horn L, Calvo E, Li A, Lin WH, Callahan MK, Spigel DR. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. *J Thorac Oncol*. 2020 Mar;15(3):426-435. doi: 10.1016/j.jtho.2019.10.004. Epub 2019 Oct 17. PMID: 31629915.
153. Owonikoko TK, Niu H, Nackaerts K, Csozsi T, Ostoros G, Mark Z, Baik C, Joy AA, Chouaid C, Jaime JC, Kolek V, Majem M, Roubec J, Santos ES, Chiang AC, Speranza G, Belani CP, Chiappori A, Patel MR, Czebe K, Byers L, Bahamon B, Li C, Sheldon-Waniga E, Kong EF, Williams M, Badola S, Shin H, Bedford L, Ecsedy JA, Bryant M, Jones S, Simmons J, Leonard EJ, Ullmann CD, Spigel DR; C14018 study investigators. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. *J Thorac Oncol*. 2020 Feb;15(2):274-287. doi: 10.1016/j.jtho.2019.10.013. Epub 2019 Oct 23. PMID: 31655296.
154. Gerber DE, Camidge DR, Morgensztern D, Cetnar J, Kelly RJ, Ramalingam SS, Spigel DR, Jeong W, Scagliotti PP, Zhang S, Li M, Weaver DT, Vaikus L, Keegan M, Horobin JC, Burns TF. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. *Lung Cancer*. 2020 Jan;139:60-67. doi: 10.1016/j.lungcan.2019.10.033. Epub 2019 Nov 4. PMID: 31739184; PMCID: PMC6942685.
155. Nishio M, Felip E, Orlov S, Park K, Yu CJ, Tsai CM, Cobo M, McKeage M, Su WC, Mok T, Scagliotti GV, Spigel DR, Viraswami-Appanna K, Chen Z, Passos VQ, Shaw AT. Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. *J Thorac Oncol*. 2020 Apr;15(4):609-617. doi: 10.1016/j.jtho.2019.11.006. Epub 2019 Nov 25. PMID: 31778798.
156. Hanna NH, Schneider BJ, Temin S, Baker S Jr, Brahmer J, Ellis PM, Gaspar LE, Haddad RY, Hesketh PJ, Jain D, Jaiyesimi I, Johnson DH, Leighl NB, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Singh N,

- Spigel DR, Stabler JO, Tashbar J, Masters G. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. *J Clin Oncol*. 2020 May 10;38(14):1608-1632. doi: 10.1200/JCO.19.03022. Epub 2020 Jan 28. PMID: 31990617.
157. Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan B, Einhorn LH, Baker J, Kasbari S, Nikolinakos P, Babu S, Couture F, Leighl NB, Reynolds C, Blumenschein G Jr, Gunuganti V, Li A, Aanur N, Spigel DR. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. *J Clin Oncol*. 2020 Nov 20;38(33):3863-3873. doi: 10.1200/JCO.20.00131. Epub 2020 Sep 10. PMID: 32910710; PMCID: PMC7676888.
158. Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McClelland M, Mocchi S, Jassem J, Spigel DR. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. *N Engl J Med*. 2020 Oct 1;383(14):1328-1339. doi: 10.1056/NEJMoa1917346. PMID: 32997907.
159. Spigel DR, Jotte RM, Aix SP, Gressot L, Morgensztern D, McCleod M, Socinski MA, Daniel D, Juan-Vidal O, Mileham KF, West H, Page R, Reinmuth N, Knobler J, Chen T, Bhorre R, Wolfsteiner M, Ong TJ, Gridelli C, Thomas M; ABOUND.sqm Investigators. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial. *Clin Lung Cancer*. 2021 Jan;22(1):6-15.e4. doi: 10.1016/j.clcc.2020.09.007. Epub 2020 Sep 18. PMID: 33097414.
160. Hodi FS, Chapman PB, Sznol M, Lao CD, Gonzalez R, Smylie M, Daniels GA, Thompson JA, Kudchadkar R, Sharfman W, Atkins M, Spigel DR, Pavlick A, Monzon J, Kim KB, Ernst S, Khushalani NI, van Dijck W, Lobo M, Hogg D. Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). *Melanoma Res*. 2021 Feb 1;31(1):67-75. doi: 10.1097/CMR.0000000000000708. PMID: 33234846; PMCID: PMC7757740.
161. Faivre-Finn C, Spigel DR, Senan S, Langer C, Perez BA, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). *Lung Cancer*. 2021 Jan;151:30-38. doi: 10.1016/j.lungcan.2020.11.024. Epub 2020 Nov 26. PMID: 33285469.
162. Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2021 Mar 1;39(7):723-733. doi: 10.1200/JCO.20.01605. Epub 2021 Jan 15. Erratum in: *J Clin Oncol*. 2021 Apr 1;39(10):1190. PMID: 33449799; PMCID: PMC8078445.
163. Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, Naidoo J, Rimner A, Wu YL, Gray JE, Özgüroğlu M, Lee KH, Cho BC, Kato T, de Wit M, Newton M, Wang L, Thiyagarajah P, Antonia SJ. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. *J Thorac Oncol*. 2021 May;16(5):860-867. doi: 10.1016/j.jtho.2020.12.015. Epub 2021 Jan 19. PMID: 33476803.
164. Herbst RS, Kuriki H, Spigel DR. Atezolizumab for PD-L1-Selected Patients with NSCLC. Reply. *N Engl J Med*. 2021 Feb 11;384(6):584-585. doi: 10.1056/NEJMc2032432. PMID: 33567202.
165. Hanna NH, Robinson AG, Temin S, Baker S Jr, Brahmer JR, Ellis PM, Gaspar LE, Haddad RY, Hesketh PJ, Jain D, Jaiyesimi I, Johnson DH, Leighl NB, Moffitt PR, Phillips T, Riely GJ, Rosell R, Schiller JH, Schneider BJ, Singh N, Spigel DR, Tashbar J, Masters G. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. *J Clin Oncol*. 2021 Mar 20;39(9):1040-1091. doi: 10.1200/JCO.20.03570. Epub 2021 Feb 16. PMID: 33591844.
166. Salgia R, Boehmer LM, Celestin C, Yu H, Spigel DR. Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey. *JCO Oncol Pract*. 2021 Mar 9;OP2000899. doi: 10.1200/OP.20.00899. Epub ahead of print. PMID: 33689449.
167. Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC, Andric Z, Mocchi S, Enquist I, Komatsubara K, McClelland M, Kuriki H, Villalobos M, Phan S, Spigel DR, Herbst

- RS. Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2021 Jul 12;S1556-0864(21)02286-3. doi: 10.1016/j.jtho.2021.06.019. Epub ahead of print. PMID: 34265434.
168. Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. *Lancet Oncol*. 2021 Jul 30;S1470-2045(21)00336-3. doi: 10.1016/S1470-2045(21)00336-3. Epub ahead of print. PMID: 34339623.
169. Cho BC, Yoh K, Perets R, Nagrial A, Spigel DR, Gutierrez M, Kim DW, Kotasek D, Rasco D, Niu J, Satouchi M, Ahn MJ, Lee DH, Maurice-Dror C, Siddiqi S, Ren Y, Altura RA, Bar J. Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. *Lung Cancer*. 2021 Sep;159:162-170. doi: 10.1016/j.lungcan.2021.07.009. Epub 2021 Jul 18. PMID: 34371366.
170. Ramalingam SS, Thara E, Awad MM, Dowlati A, Haque B, Stinchcombe TE, Dy GK, Spigel DR, Lu S, Iyer Singh N, Tang Y, Teslenko I, Iannotti N. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. *Cancer*. 2021 Sep 3. doi: 10.1002/cncr.33885. Epub ahead of print. PMID: 34478166.
171. Moore KN, Chambers SK, Hamilton EP, Chen LM, Oza AM, Ghamande SA, Konecny GE, Plaxe SC, Spitz DL, Geenen JJJ, Troso-Sandoval TA, Cragun JM, Rodrigo Imedio E, Kumar S, Mugundu GM, Lai Z, Chmielecki J, Jones SF, Spigel DR, Cadoo KA. Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. *Clin Cancer Res*. 2022 Jan 1;28(1):36-44. doi: 10.1158/1078-0432.CCR-21-0158. Epub 2021 Oct 13. PMID: 34645648.
172. Friedman CF, Hainsworth JD, Kurzrock R, Spigel DR, Burris HA, Sweeney CJ, Meric-Bernstam F, Wang Y, Levy J, Grindheim J, Shames DS, Schulze K, Patel A, Swanton C. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. *Cancer Discov*. 2022 Mar 1;12(3):654-669. doi: 10.1158/2159-8290.CD-21-0450. PMID: 34876409
173. Sturgill EG, Misch A, Lachs R, Jones CC, Schlauch D, Jones SF, Shastry M, Yardley DA, Burris HA 3rd, Spigel DR, Hamilton EP, McKenzie AJ. Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics. *JCO Precis Oncol*. 2021 Nov;5:1297-1311. doi: 10.1200/PO.20.00469. PMID: 34994634.
174. Schlauch D, Fu X, Jones SF, Burris HA 3rd, Spigel DR, Reeves J, McKenzie AJ. Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. *JCO Precis Oncol*. 2021 Nov;5:1625-1638. doi: 10.1200/PO.21.00008. PMID: 34994650.
175. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Özgüroğlu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2022 Apr 20;40(12):1301-1311. doi: 10.1200/JCO.21.01308. Epub 2022 Feb 2. Erratum in: *J Clin Oncol*. 2022 Jun 10;40(17):1965. PMID: 35108059; PMCID: PMC9015199.
176. Hrinchenko B, Iannotti N, Goel S, Spigel D, Safran H, Taylor MH, Bennouna J, Wong DJ, Kelly K, Verschraegen C, Bajars M, Manitz J, Ruisi M, Gulley JL. Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor. *Future Oncol*. 2022 Apr;18(11):1333-1342. doi: 10.2217/fo-2021-0930. Epub 2022 Feb 11. PMID: 35144482; PMCID: PMC9066292.
177. Paz-Ares L, Spigel DR, Chen Y, Jove M, Juan-Vidal O, Rich P, Hayes T, Calderón VG, Caro RB, Navarro A, Dowlati A, Zhang B, Moore Y, Yao X, Kokhraidze J, Ponce S, Bunn PA. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer. *Cancer*. 2022 May 1;128(9):1801-1811. doi: 10.1002/cncr.34123. Epub 2022 Feb 23. PMID: 35195913.
178. Sturgill EG, Misch A, Jones CC, Lockett D, Fu X, Schlauch D, Jones SF, Burris HA, Spigel DR, McKenzie AJ. Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune

Checkpoint Inhibition in Real-World Settings. *Oncologist*. 2022 Mar 11;27(3):175-182. doi: 10.1093/oncolo/oyab064. PMID: 35274716; PMCID: PMC8914506.

179. Pennell NA, Szczepanek C, Spigel D, Ramalingam SS. Impact of Workforce Challenges and Funds Flow on Cancer Clinical Trial Development and Conduct. *Am Soc Clin Oncol Educ Book*. 2022 Apr;42:1-10. doi: 10.1200/EDBK_360253. PMID: 35439037.

180. Brown J, Scardo S, Method M, Schlauch D, Misch A, Picard S, Hamilton E, Jones S, Burris H, Spigel D. A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States. *BMC Cancer*. 2022 May 6;22(1):502. doi: 10.1186/s12885-022-09557-6. PMID: 35524219; PMCID: PMC9074265.

181. Singh N, Temin S, Baker S Jr, Blanchard E, Brahmer JR, Celano P, Duma N, Ellis PM, Elkins IB, Haddad RY, Hesketh PJ, Jain D, Johnson DH, Leighl NB, Mamdani H, Masters G, Moffitt PR, Phillips T, Riely GJ, Robinson AG, Rosell R, Schiller JH, Schneider BJ, Spigel DR, Jaiyesimi IA. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. *J Clin Oncol*. 2022 Jul 11;JCO2200824. doi: 10.1200/JCO.22.00824. Epub ahead of print. PMID: 35816666.

Reviews

182. Spigel DR, Burstein HJ. HER2 overexpressing metastatic breast cancer. *Current Treatment Options in Oncology* 2002; 3(2): 163-174.

183. Spigel DR, Greco FA. Evolving Role of Irinotecan in Small Cell Lung Cancer. *Clinical Advances in Hematology/Oncology*. 2003; 1(8): 482-485.

184. Spigel DR, Greco FA. Chemotherapy in Metastatic and Locally Advanced Non-Small Cell Lung Cancer. *Seminars in Surgical Oncology* 2003; 21(2):98-110.

185. Spigel DR, Burstein HJ. Trastuzumab Regimens for HER2-Overexpressing Breast Cancer, *Clinical Breast Cancer*, 2003, 4(5):329-337.

186. Spigel DR. Chapter 13, Lifestyle modifications. *Facing Cancer*. Sekeres and Stern Eds, 2003, 161-170; in press.

187. Spigel DR, Greco FA. "Carcinoma of Unknown Primary" *Hematology-Oncology Therapy*, McGraw Hill Medical: 2006, 80-84.

188. Spigel DR, Greco FA. "Cancer of Unknown Primary Site" *Surgical Oncology, Clinical Scenarios in Surgical Oncology*. Lippincott: 2005. Pg 409.

189. Spigel DR, Greco FA. "What is the Role of Novel Taxanes in NSCLC?" *Clinical Lung Cancer*. 9 (Supp 3), 2008, S116-121.

190. Spigel DR. PRISM: a study of second-line panitumumab monotherapy for treatment of advanced head and neck cancer. *Community Oncology* 2008, 5(suppl 11):1-4.

191. Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. *Seminars in Oncology*. 36(1):52-9, 2009 Feb.

192. Spigel DR, The value of observational cohort studies for cancer drugs. *Biotechnol Healthc Summer* 2010;7(2):18-24.

193. Socinski MA, Govindan R, Spigel D. Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer. *Clin Adv Hematol Oncol*. 2012 Oct;10(10 Suppl 18):1-16.

194. Spigel DR. PARP inhibitors in lung cancer. *J Thorac Oncol*. 2012 Dec;7(16 Suppl 5):S392-3.

195. Spigel DR. Treatment update in small-cell lung cancer: from limited to extensive disease. *Curr Treat Options Oncol*. 2012 Dec;13(4):505-15.

196. Spigel DR, Socinski MA. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. *J Thorac Oncol*. 2013 May;8(5):587-98. doi: 10.1097/JTO.0b013e318286cf88. Review. PubMed PMID: 23546044.
197. Jotte RM, Spigel DR. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. *Cancer Med*. 2015 Nov;4(11):1621-32. doi: 10.1002/cam4.506. Epub 2015 Aug 26. PubMed PMID: 26310719.
198. Zinner R, Visseren-Grul C, Spigel DR, Obasaju C. Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer. *Int J Oncol*. 2016 Jan;48(1):13-27. doi: 10.3892/ijo.2015.3219. Epub 2015 Oct 29.
199. Horn L, Reck M, Spigel DR. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. *Oncologist*. 2016 Jun 27.
200. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N. Clinicopathologic features of advanced squamous non-small cell lung cancer. *J Thorac Oncol*. 2016 Jun 10. pii: S1556-0864(16)30499-3.
201. Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. *J Thorac Oncol*. 2016 Dec;11(12):2066-2081.
202. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. *J Thorac Oncol*. 2017 Aug;12(8):1183-1209.
203. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA Jr, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. *J Thorac Oncol*. 2018 Feb;13(2):165-183. doi: 10.1016/j.jtho.2017.11.111. Epub 2017 Nov 23. PMID: 29175116.
204. Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. *Clin Lung Cancer*. 2018 Jul;19(4):331-339. doi: 10.1016/j.clcc.2018.03.014. Epub 2018 Mar 21. PMID: 29773328.

Case Reports

205. Bronze MS, Warr AG, Spigel DR, Smith VD, Smalley D. False-positive enzyme immunoassay for human immunodeficiency virus due to acute cytomegalovirus infection. *Clinical Infectious Diseases*. 1998; 27(1):221-2.
206. Stoffel EM, Spigel DR, Grace ND. Waldenstrom's macroglobulinemia presenting as new-onset ascites. *Journal of Hepatology*. 41(4):689-90, 2004

Editorials/Commentaries

207. Spigel DR, Burstein H. Fournier et al Article Reviewed. *Oncology*. October 2002;16(10):1352-1356.
208. Spigel DR, Winer E. Editorial: Quality of Life in Breast Cancer Survivors. *Journal of Clinical Outcomes Management*. 2002;9(3):123-126.
209. Spigel DR. Editorial: Screening for Lung Cancer with Low-Dose Helical Computed Tomography: Are We Getting Closer? *Journal of Clinical Outcomes Management*. 2002;9(4):182-183.

210. Spigel DR. Editorial: Lowering the Risk of Prostate Cancer with NSAIDs: Moving Towards Chemoprevention. *Journal of Clinical Outcomes Management*. 2002;9(5):239-242.
211. Spigel DR. Editorial: Positron Emission Tomography to Improve Care for Patients with Suspected Non-Small Cell Lung Cancer. *Journal of Clinical Outcomes Management*. 2002;9(6):303-302.
212. Spigel DR. Editorial: Evaluating Suspected Breast Cancer at a One Stop Clinic: Is this a Better Model? *Journal of Clinical Outcomes Management*. 2002;9(7):365-366.
213. Spigel DR. Editorial: PSA and Overdiagnosis: Can Computers Sort This Out? *Journal of Clinical Outcomes Management*. 2002;9(8):433-434.
214. Spigel DR. Editorial: Improving Colon Cancer Survival with Surgical Technique. *Journal of Clinical Outcomes Management* 2002; 9(9):485-489.
215. Spigel DR. Editorial: Is Anticoagulation in Patients with Cancer Safer Using Low Molecular Weight Heparin? *Journal of Clinical Outcomes Management*. 2002;9(10):545-546.
216. Spigel DR. Editorial: Helping Patients with Lung Cancer Quit Smoking: An Attainable Goal. *Journal of Clinical Outcomes Management*. 2002;9(11):609-610.
217. Spigel DR. Editorial: Patient-Managed Anticoagulation: Effective but More Costly *Journal of Clinical Outcomes Management*. 2002;9(12):655-656.
218. Spigel DR, Winer E. Garrison et al Article Reviewed. *Oncology*. February 2003;17(2):281-282.
219. Spigel DR. Editorial: Following Patients with Advanced Cancer: Satisfaction with Nurse-led Care *Journal of Clinical Outcomes Management*. 2003;10(1): 16-18.
220. Spigel DR. Editorial: Evaluating Suspected Malignant Pleural Effusions: Is Sending More Fluid Better? *Journal of Clinical Outcomes Management*. 2003;10(2): 67-68.
221. Spigel DR. Editorial: Improving Appetite in Patients with Advanced Cancer: Putting Fish Oil to the Test *Journal of Clinical Outcomes Management*. 2003;10(3):129-130.
222. Spigel DR. Editorial: Value of Short-term Follow-up Recommendations in Mammography *Journal of Clinical Outcomes Management*. 2003; 10(5):250-251.
223. Spigel DR. Editorial: Targeting Repeat Blood Donors Can Increase Supply *Journal of Clinical Outcomes Management*. 2003; 10(6):303-304.
224. Spigel DR. Editorial: Surgery and Survival in Rectal Cancer: Benefits of High Volume Hospitals *Journal of Clinical Outcomes Management*. 2003; 10(7): 361-363.
225. Spigel, DR. Commentary: HER2 and Surgery: More Questions to Answer. *The Lancet*. 2003; 362(9383): 502-503 .
226. Spigel DR. Editorial: Implementing Cervical Cancer Screening in Underserved Communities *Journal of Clinical Outcomes Management*. 2003; 10(8): 405-406.
227. Spigel DR, Winer E. Feyler: Commentary. *Breast Diseases: A Year Book Quarterly*. May 2003.
228. Spigel DR. Editorial: Screening for Colorectal Lesions: How Well Does Virtual Colonoscopy Perform? *Journal of Clinical Outcomes Management*. 2003; 10(9): 463-464.
229. Spigel DR. Editorial: Improved Outcomes with Perioperative Erythropoietin. *Journal of Clinical Outcomes Management*. 2003; 10(10): 523-524.
230. Spigel DR. Editorial: Catheter Design and Bacteremia in Patients with Cancer. *Journal of Clinical Outcomes Management*. 2003; 10(11): 584-585.

231. Spigel DR. Editorial: Adopting New Breast Cancer Staging: The Impact of Stage Migration. *Journal of Clinical Outcomes Management*. 2003; 10(12): 638,641.
232. Spigel DR. Editorial: Specialist Referral versus Direct Testing: Optimizing Care of Patients with Colorectal Symptoms. *Journal of Clinical Outcomes Management*. 2004; 11(1): 10-11.
233. Spigel DR. Editorial. Review of M. Martin et al "Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines". *The Women's Oncology Review*. 2003; 3(4): in press.
234. Spigel DR. Editorial: Treatment Delay and Survival In Patients with Non-Small Cell Lung Cancer. *Journal of Clinical Outcomes Management*. 2004; 11(2): 68, 71.
235. Spigel DR. Editorial: Recording Physician-Patient Visits: Minimal Cost, Minimal Gain. *Journal of Clinical Outcomes Management*. 2004; 11(3): 141-142.
236. Spigel DR. Editorial: Adherence to Screening Guidelines for Colorectal Cancer: the Impact of Genetic Testing and Counseling. *Journal of Clinical Outcomes Management*. 2004; 11(4): 201-205.
237. Spigel DR. Editorial: Reducing Mammography-Associated Anxiety with Rapid Reporting. *Journal of Clinical Outcomes Management*. 2004; 11(5): 270-274.
238. Spigel DR. Editorial: Impact of Biopsy Strategy on Prostate Cancer Detection Rates. *Journal of Clinical Outcomes Management*. 2004; 11(6): 330-331.
239. Spigel DR. Editorial: Early Genetic Counseling and Testing for Breast Cancer Patients and Impact on Surgical Decision. *Journal of Clinical Outcomes Management*. 2004; 11(7): 408,412.
240. Spigel DR. Editorial: Staging Lung Cancer Using Positron Emission Tomography and the Impact on Care. *Journal of Clinical Outcomes Management*. 2004; 11(8): 486-488.
241. Spigel DR. Editorial: Reducing Bone Loss from Androgen Deprivation in Prostate Cancer. *Journal of Clinical Outcomes Management*. 2004; 11(9): 552, 555.
242. Spigel DR. Editorial: Improving Neuropathic Pain Due To Cancer Using Gabapentin. *Journal of Clinical Outcomes Management*. 2004; 11(10): 620-621.
243. Spigel DR. Editorial: Improving Diagnostic Accuracy in Patients with Suspected Lymphoma. *Journal of Clinical Outcomes Management*. 2004; 11(11): 691-692.
244. Spigel DR. Editorial: Weekly Erythropoietin Improves Anemia Associated with Cancer Treatment. *Journal of Clinical Outcomes Management*. 2004; 11(12): 751-752.
245. Spigel DR. Editorial: Timing Therapy in Patients with Prostate Cancer. *Journal of Clinical Outcomes Management*. 2005; 12(1): 15, 18.
246. Spigel DR. Editorial: Pain Education for Minority Patients with Cancer. *Journal of Clinical Outcomes Management*. 2005; 12(2): 75, 78.
247. Spigel DR. Editorial. Review of M. Cristofanilli's: "Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *New England Journal of Medicine*. 351(8):781-91, 2004. *The Women's Oncology Review*. 2005; 5(2): 115-116.
248. Spigel DR. Editorial: Radiation Improves Overall Survival after Mastectomy in Women with Node-Positive Breast Cancer. *Journal of Clinical Outcomes Management*. 2005; 12(3): 131, 134.
249. Spigel DR. Editorial: Improved Colorectal Cancer Screening Rates with Provider Training. *Journal of Clinical Outcomes Management*. 2005; 12(4): 189-190.
250. Spigel DR. Editorial: Low Molecular weight Heparin Improves Survival in Patients with Cancer. *Journal of Clinical Outcomes Management*. 2005; 12(5): 241-242.

251. Spigel DR. Editorial: Cancer Prevention After Head and Neck Cancer Using Vitamin E. *Journal of Clinical Outcomes Management*. 2005; 12(6): 285, 288.
252. Spigel DR. Editorial: Comparing Group and Individual Breast Cancer Genetic Counseling. *Journal of Clinical Outcomes Management*. 2005; 12(7): 338-339.
253. Spigel DR. Editorial: Omitting Axillary Dissection in Early-Stage Breast Cancer. *Journal of Clinical Outcomes Management*. 2005; 12(8): 388-389.
254. Spigel DR. Editorial: Single-Fraction Radiation Effective for Patients with Painful Skeletal Metastases. *Journal of Clinical Outcomes Management*. 2005; 12(9): 439-440.
255. Spigel DR. Editorial: Concurrent Chemoradiation Scheduling May Improve Lung Cancer Survival. *Journal of Clinical Outcomes Management*. 2005; 12(10): 499, 502.
256. Spigel DR. Editorial: Hormone Replacement Therapy Increases Breast Density on Mammography. *Journal of Clinical Outcomes Management*. 2005; 12(11): 557-558.
257. Spigel DR. Editorial: Improved Quality of Life with Laparoscopic Treatment in Early-Stage Endometrial Cancer. *Journal of Clinical Outcomes Management*. 2005; 12(12): 602-603.
258. Spigel DR. Editorial: Using Disease-Free Survival as an Alternate Endpoint in Colorectal Cancer Patients. *Journal of Clinical Outcomes Management*. 2006; 13(1): 23-24.
259. Spigel DR. Editorial: Improving Rates of Colorectal Cancer Screening: No Easy Answers. *Journal of Clinical Outcomes Management*. 2006; 13(2): 87-88.
260. Spigel DR. Editorial: Surveillance After Colorectal Cancer Surgery. *Journal of Clinical Outcomes Management*. 2006; 13(3): 143-144.
261. Spigel DR. Editorial: Delayed versus Immediate Prostatectomy: The Question of Cancer Curability. *Journal of Clinical Outcomes Management*. 2006; 13(4): 202, 207.
262. Spigel DR. Editorial: Outcomes for Family Physician Follow-Up Care for Early-Stage Breast Cancer Similar to Specialty Care. *Journal of Clinical Outcomes Management*. 2006; 13(5): 257-258.
263. Spigel DR. Editorial: Reduced Morbidity Using Sentinel Node Biopsy in Breast Cancer Patients. *Journal of Clinical Outcomes Management*. 2006; 13(8): 436-437.
264. Spigel DR. Medscape Review: Journal Scan - The Latest Findings in Biologic Therapies. Vol 1. <http://www.medscape.com/viewprogram>.
265. Spigel DR. Medscape Review: Journal Scan - The Latest Findings in Biologic Therapies. Vol 2. <http://www.medscape.com/viewprogram>.
266. Spigel DR. Medscape Review: Journal Scan - The Latest Findings in Biologic Therapies. Vol 3. <http://www.medscape.com/viewprogram>.

Abstracts / Oral Presentations: 2002-Current (Available Upon Request)